Prelude Therapeutics Inc
Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. The Company’s product candidate pipeline includes PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT3645. PRT543 is in a Phase I clinical trial in advanced solid tumors and select myeloid malignancies. PRT811 is a being studied in a Phase I clinical trial in unselected patients with solid tumors, including high-grade glioma. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is designed to be a potent and selective Cyclin-dependent kinase 9 (CDK9), inhibitor. The Company’s drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders.
Buy US stocks in Australia starting with PRLD. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PRLD
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.